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Background: Left ventricular diastolic impairment and consequently elevated filling pressure may contribute to
stasis leading to left atrial appendage thrombus (LAAT) in nonvalvular atrial fibrillation (AF). We investigated
whether transthoracic echocardiographic parameters can predict LAAT independent of traditional clinical predictors.
Methods: We conducted a retrospective cohort study of 297 consecutive nonvalvular AF patients who underwent
transthoracic echocardiogram followed by a transesophageal echocardiogram within one year. Multivariate logistic
regression analysis models were used to determine factors independently associated with LAAT.
Results: Nineteen subjects (6.4%) were demonstrated to have LAAT by transesophageal echocardiography. These
patients had higher mean CHADS2 scores [2.6 ± 1.2 vs. 1.9 ± 1.3, P = 0.009], higher E:e’ ratios [16.6 ± 6.1 vs. 12.0 ± 5.4,
P = 0.001], and lower mean e’ velocities [6.5 ± 2.1 cm/sec vs. 9.1 ± 3.2 cm/sec, P = 0.001]. Both E:e’ and e’ velocity
were associated with LAAT formation independent of the CHADS2 score, warfarin therapy, left ventricular ejection
fraction (LVEF), and left atrial volume index (LAVI) [E:e’ odds-ratio = 1.14 (95% confidence interval = 1.03 – 1.3),
P = 0.009; e’ velocity odds-ratio = 0.68 (95% confidence interval = 0.5 – 0.9), P = 0.007]. Similarly, diastolic function
parameters were independently associated with spontaneous echo contrast.
Conclusion: The diastolic function indices E:e’ and e’ velocity are independently associated with LAAT in
nonvalvular AF patients and may help identify patients at risk for LAAT.
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Nonvalvular atrial fibrillation (AF) is the most common
sustained cardiac dysrhythmia and the most frequent
cause of cardio-embolic stroke [1]. It is well known that
left atrial appendage thrombi (LAAT) are the source of
most embolic strokes in patients with nonvalvular AF
[2,3]. It is, likewise, widely accepted that transesophageal
echocardiography (TEE) can identify LAAT and left
atrial blood stasis, manifesting as spontaneous echo con-
trast (SEC), a known precursor of LAAT and systemic
thromboembolism (Figure 1) [4-6].* Correspondence: rami_doukky@rush.edu
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unless otherwise stated.It is physiologically plausible that impaired diastolic
function and consequent elevation in the left ventricu-
lar filling pressure (LVFP) lead to left atrial stasis which
results in LAAT formation and subsequent risk of sys-
temic thromboembolism. Prior reports suggest that
two-dimensional echocardiographic parameters such as
left ventricular ejection fraction (LVEF), left atrial vol-
ume index (LAVI) and LVEF/LAVI are associated with
LAAT in patients with AF [7,8]. In this investigation,
we sought to determine whether e’ velocity (as a surro-
gate for left ventricular relaxation) and E:e’ (as a meas-
ure of left ventricular filling pressure) are predictive of
LAAT formation and SEC independent of confounding
covariates. Furthermore, we sought to integrate dia-
stolic function indices with other echocardiographicLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Representative examples. A: left atrial spontaneous echo contrast (SEC). B: left atrial appendage thrombus (arrow). C: Pulsed-wave Doppler
recording of early diastolic mitral inflow velocity (E). D: Spectral tissue Doppler imaging of the lateral mitral annulus early diastolic velocity (e’).
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patients with nonvalvular AF.
Methods
Patient population and study design
A retrospective cohort study design was implemented.
We queried the echocardiography laboratory database at
Rush University Medical Center to identify all consecu-
tive adult patients with nonvalvular AF who underwent
a TEE to “rule-out” left atrial appendage thrombus be-
tween January 1, 2005 and December 31, 2009. Of those,
we only included patients who had a previous transtho-
racic echocardiogram (TTE) within 1 year of the TEE.
Patients with atrial flutter, without intervening episodes
of atrial fibrillation, were not included. We excluded pa-
tients with valvular AF due to mitral stenosis and those
with conditions known to alter E and e’ velocities;
namely mitral regurgitation greater than 2+ in severity
(on a 0 to 4 scale), post mitral valve surgical or percu-
taneous intervention, and post orthotopic heart trans-
plantation status. Patients with isolated aortic valvulardisease, aortic valve prostheses and right-sided valvular
heart disease were not excluded [1].
An expert board-certified (NBE) echocardiographer (RD),
who was blinded to the TTE and clinical data, reviewed all
TEE images to determine the presence or absence of LAAT
[LAAT(+) and LAAT(−)], SEC and depressed left atrial ap-
pendage emptying velocity (<40 cm/sec) by pulsed-
wave Doppler. LAAT was defined as a circumscribed
and uniformly echodense intracavitary mass distinct
from the underlying left atrial or left atrial appendage
endocardium and the pectinate muscles, and present in
more than one imaging plane [9]. Left atrial appendage
sludge, defined as a dynamic gelatinous, precipitous
echodensity, without a discrete mass, present through-
out the cardiac cycle was categorized as LAAT [10,11].
SEC was defined as dynamic “smoke-like” echoes with
the characteristic swirling motion with optimal gain
setting during the entire cardiac cycle [12].
All TTEs were reviewed offline by a board-certified
(NBE) echocardiographer who was blinded to TEE and
clinical data (HG). The mitral inflow early-diastolic
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nulus tissue Doppler early-diastolic velocity (e’) were mea-
sured (cm/sec) and the E:e’ ratio was calculated (Figure 1).
We did not analyze e’ velocities sampled from the medial
mitral annulus, since this was not routinely obtained ac-
cording to our laboratory protocol at the time when the
study TTEs were performed (2005–2009). The Doppler
measurements were obtained by averaging data from 3–5
consecutive beats. The left ventricular septal and posterior
wall thicknesses and end-diastolic as well as end-systolic
internal dimensions were measured from 2-dimentional
and M-mode TTE images [13]. The left ventricular mass
was calculated using the Devereux formula [14]. The left
ventricular systolic and diastolic volumes and LVEF were
measured using the biplane Simpson’s method or the
Teichholz formula only when the former was not feasible
due to suboptimal apical views [13,15]. The left atrial di-
mensions (antero-posterior, medio-lateral and supero-
inferior) were measured and the left atrial volume was
calculated using the formula [4/3π (D1/2) (D2/2) (D3/
2)] where each “D” represents one of three atrial di-
mensions [13]. All volume and mass measurements
were indexed to the body surface area. The heart
rhythm during TTE acquisition was determined from
examination of the rhythm strip on the screen display.
Finally, a detailed chart review was performed to col-
lect data on demographics, comorbidities, anticoagulant
and antiplatelet use, and INR (international normalized
ratio). Congestive heart failure (CHF) was defined as any
clinical heart failure or LVEF < 40%. Date-of-onset and
chronicity of AF were determined from patients’ health
records. Paroxysmal AF was defined as AF spontan-
eously reverting to sinus rhythm within 7 days from on-
set. Persistent AF was defined as AF lasting more than
7 days, but less than 6 months, or any AF events termi-
nated by electrical or chemical cardioversion or radiofre-
quency ablation within 6 months from onset. Permanent
AF was defined as lasting more than 6 months [1]. The
CHADS2 score was calculated from the sum of risk pre-
dictors of CHF, hypertension, age ≥75, diabetes mellitus,
stroke or transient ischemic attack (TIA); weighing each
by “1” except for prior stroke/transient ischemic attack
(TIA) which was weighed by “2” [16]. The CHA2DS2-
VASc score was calculated from the sum of the risk
factors of CHF, hypertension, age 65–74 or ≥75 years,
diabetes mellitus, stroke/TIA, vascular disease, female
gender; weighing each by “1” except for stroke/TIA and
age ≥75 which were weighed by “2” [17]. The primary
outcome of the study was TEE-identified LAAT. The
secondary outcome was TEE-identified SEC.
Statistical analysis
The two-tailed Student’s t-test was used to compare
normally-distributed continuous variables which wereexpressed as mean ± standard deviation (SD). The Mann–
Whitney-U test was used to compare continuous vari-
ables that did not adhere to a normal distribution
which were expressed as median (interquartile range).
The Shapiro-Wilk test was used to confirm the normal-
ity of data. The chi-square (χ2) test was used to com-
pare categorical variables which were expressed as
frequency [n (%)]. The Spearman’s method was used to
evaluate linear correlations.
Multivariate logistic regression analysis models were
used to determine clinical and echocardiographic predic-
tors of outcome measures independent of known con-
founders. Risk was expressed as odd-ratios (OR) with
95% confidence intervals (CI). The Hosmer-Lemeshow
test was used to test regression models’ goodness of fit.
The receiver operating characteristic (ROC) method-
ology was used to analyze the discriminatory capacity of
various predictors of LAAT. ROC analyses were expressed
as curve plots with the associated area under the curve
(AUC) with 95% CI and a P value representing the like-
lihood of the null hypothesis (AUC = 0.5). A two-tailed
P value ≤0.05 was considered statistically significant in
all analyses. PASW-18 software (SPSS, Inc. - Chicago, IL)
was used for all data analyses with the exception of the
comparisons between ROC curves for which STATA-11
(College Station, TX) was used. The study was funded by
an internal research grant and was approved by the Rush
University Medical Center institutional review board.
Results
A database query yielded 527 TEEs performed in pa-
tients with nonvalvular AF to “rule-out” LAAT. Of
those, 167 were excluded due to mitral valvular disease
and 63 for not having had a TTE performed at our insti-
tution within a year prior to the TEE. Consequently, a
cohort of 297 consecutive TEEs in adult subjects with
nonvalvular AF met the inclusion criteria. The electro-
physiological procedures that prompted the TEE were:
cardioversion in 131 (44.1%), AF ablation in 99 (33.3%),
implantation and testing of an implantable cardioverter-
defibrillator in 45 (15.2%), and revision and testing of an
implantable cardioverter-defibrillator in 22 (7.4%) sub-
jects. The median interval between the TTE and TEE
was 7.5 days (interquartile range 2–93 days). The mean
INR within 30 days prior to the TEE for warfarin-treated
patients was 1.7 ± 0.8. Nineteen subjects (6.4%) had a
TEE proven LAAT. At the time of the TTE, 98 (33%)
subjects were in sinus rhythm, 178 (60%) in AF or atrial
flutter, and 21 (7%) in paced ventricular rhythm. Not-
ably, patients with LAAT had a significantly higher mean
CHADS2 score, along with an increase in warfarin use
(Table 1). Prior to the TEE, adequate anticoagulation
was confirmed in 14 (74%) subjects with LAAT, and
twelve of these (86%) had a CHADS2 score ≥2. AF
Table 1 Baseline clinical characteristics
LAAT (+) LAAT (−) P
valueN = 19 N = 278
Age (years), mean ± SD 66 ± 13 62 ± 14 0.37
Age ≥ 75 years, n (%) 5 (26%) 55 (20%) 0.49
Male gender, n (%) 14 (74%) 176 (63%) 0.36
Hypertension, n (%) 16 (84%) 177 (64%) 0.07
Diabetes mellitus, n (%) 8 (42%) 73 (26%) 0.13
Congestive heart failure,
n (%)
15 (79%) 132 (47%) 0.01
History of stroke or TIA,
n (%)
2 (11%) 27 (10%) 0.91
Aspirin, n (%) 9 (47%) 122 (44%) 0.79
Clopidogrel, n (%) 2 (11%) 16 (6%) 0.41
Antiplatelet, n (%) 10 (53%) 126 (46%) 0.56
Warfarin, n (%) 15 (79%) 148 (53%) 0.03
CHADS2 score, mean ± SD 2.6 ± 1.2 1.9 ± 1.3 0.009*
CHA2DS2-VASc Score,
mean ± SD
3.5 ± 1.7 2.8 ± 1.8 0.08*
CHADS2 Score ≥ 2, n (%) 17 (89%) 158 (57%) 0.005
Duration since first AF
episode (days), median
(interquartile range)
691.5 (90–1163) 162 (4–1249) 0.28*
AF type, n (%)
● Paroxysmal 8 (42%) 153 (55%) 0.27
● Persistent 4 (21%) 58 (21%) 0.98
● Permanent 7 (37%) 67 (24%) 0.21
Creatinine (mg/dL),
mean ± SD
1.6 ± 0.7 1.4 ± 1.0 0.047*
LAAT: left atrial appendage thrombus; SD: standard deviation; TIA: transient
ischemic attack; AF: atrial fibrillation. *Mann–Whitney U test.
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with and without LAAT (Table 1).
Compared to the 297 analyzed subjects, the 63 pa-
tients excluded for lacking a qualifying TTE had no sig-
nificant differences in the prevalence of LAAT [3 (4.8%)
vs. 19 (6.4%), P = 0.62], mean age (59 ± 17 vs. 63 ±
14 years, P = 0.13), mean CHADS2 score (2.1 ± 1.3 vs.
1.9 ± 1.3, P = 0.20), and gender distribution [41 (65%) vs.
190 (64%) men, P = 0.87]. Furthermore, they had a simi-
lar prevalence of CHF, age ≥75 years, diabetes, stroke/
TIA history, and warfarin use (all P values >0.18).
E:e’ and e’ velocity association with LAAT
The mean E:e’ among LAAT(+) patients was significantly
higher than those who were LAAT(−) [16.6 ± 6.1 vs.
12.0 ± 5.4, respectively; P = 0.001]. Conversely, the e’ vel-
ocity was significantly lower among LAAT(+) subjects
[6.5 ± 2.1 vs. 9.1 ± 3.2, P = 0.006] (Figure 2, Table 2).
Among LAAT(+) subjects, none (0%) had a normal E:e’
of ≤8; whereas 16 (84%) had an E:e’ ≥ 12, indicative ofelevated LVFP [18]. Furthermore, there was a stepwise
increase in the prevalence of LAAT with increasing E:e’
and decreasing e’ velocity (Figure 3). Additionally, LAAT
(+) subjects had a significantly higher LAVI and left ven-
tricular volume index but lower LVEF (Table 2). Not
surprisingly, there was a modest, but highly statistically
significant, linear correlation between the CHADS2 score
and diastolic indices of the E:e’ and e’ velocity, with
Spearman’s correlation coefficients “r” of 0.34 (P < 0.001)
and −0.32 (P < 0.001), respectively. Since only a minority
of the patients (33%) were in sinus rhythm at the time of
TTE, and thus had no A wave in the mitral inflow Doppler
waveforms, it was not feasible to classify the patients based
on their grade of diastolic dysfunction (typically graded
from I to IV).
A multivariate logistic regression analysis demonstrated
that the CHADS2 score is associated with LAAT inde-
pendent of warfarin use [OR = 1.47 per one point
CHADS2 score increment (CI = 1.04-2.1), P = 0.03], while
warfarin use had a borderline association with LAAT
(Table 3; Model-1). When E:e’ was added to Model-1, it
was independently associated with LAAT [OR = 1.14 per 1
point increment (CI = 1.05-1.2), P =0.002] and negated the
effect of the CHADS2 score (Model-2, Table 3). To ensure
that this association is not simply a confounder to im-
paired left ventricular function and left atrial volume, we
added LVEF and LAVI to the model forming Model-3, in
which E:e’, LVEF and LAVI were independently associated
with LAAT, whereas the value of the CHADS2 and war-
farin use was further negated (Table 3, Model-3).
Similarly, when e’ velocity then LVEF and LAVI were se-
quentially introduced to Model-1 (Models 4 and 5), e’ vel-
ocity was independently “protective” of LAAT after
adjusting for other covariates [OR = 0.68 for each 1 cm/sec
increment in e’ velocity, P = 0.007] while the CHADS2
score was not (Table 3; Model-5). The Hosmer and Leme-
show test demonstrated a good fit of Models 3 and 5
(Table 3). Nearly identical results were obtained when ana-
lyzing the CHA2DS2-VASc score instead of CHADS2
score.
Additionally, E:e’ and e’ velocity were also associated
with LAAT independent of the individual components
of CHADS2 score [E:e’ odds-ratio = 1.07 per 1 point in-
crement (CI = 1.01-1.14), P = 0.02; e’ velocity odds-ratio
= 0.87 per 1 cm/sec increment (CI = 0.77-0.98), P = 0.03].
These models maintained a good model fit (Hosmer and
Lemeshow test P values = 0.30 and 0.23, respectively).
Similar findings were noted with the CHA2DS2-VASc
score.
We did not test E:e’ and e’ velocity in a single regres-
sion model due to inherent co-linearity between these
parameters. However, we compared (using ROC ana-
lysis) the diagnostic performance of the predicted prob-
abilities of LAAT derived from an E:e’ based regression
Figure 2 Box plots: E:e’ ratio and e’ velocity.
Table 2 Univariate analysis: Echocardiographic
parameters
LAAT (+) LAAT (−) P
valueN = 19 N = 278
E:e’ ratio, mean ± SD 16.6 ± 6.1 12.0 ± 5.4 0.001
E:e’ > 8, n (%) 19 (100%) 195 (70%) 0.006
E:e’ ≥ 12, n (%) 16 (84%) 127 (46%) 0.001
e’ velocity (cm/sec),
mean ± SD
6.5 ± 2.1 9.1 ± 3.2 0.001
Spontaneous echo
contrast, n (%)
19 (100%) 95 (34%) < 0.001
Depressed LAA emptying
velocity*, n (%)
19 (100%) 132 (48.0%) < 0.001
LA volume index (mL/m2),
mean ± SD
44 ± 13 30 ± 13 < 0.001
LV volume index (mL/m2),
mean ± SD
96 ± 38 73 ± 35 0.01
LV mass index (g/m2),
mean ± SD
124 ± 45 124.0 ± 44 1.0
LVEF (%), mean ± SD 26 ± 17 45 ± 20 < 0.001
LAAT: left atrial appendage thrombus; SD: standard deviation; LAA: left atrial
appendage; LA: left atrial; LV: left ventricular; LVEF: left ventricular
ejection fraction.
*LAA emptying velocity < 40 cm/sec.
Doukky et al. Cardiovascular Ultrasound 2014, 12:10 Page 5 of 9
http://www.cardiovascularultrasound.com/content/12/1/10model (Model-3) versus an e’ velocity based one
(Model-5). This analysis demonstrated that the contribu-
tion of E:e’ and e’ velocity to the prediction of LAAT
was comparable, as the AUC associated with models 3
and 5 were similar (0.86 and 0.87, respectively; P = 0.33).
E:e’ and e’ velocity association with SEC
One-hundred fourteen subjects (38%) had significant
SEC by TEE, including all 19 subjects (100%) with LAAT
(Table 2). These patients, as compared to those without
SEC, had significantly higher mean E:e’ [14.2 (±5.6) vs.
11.4 (±5.4), P = 0.001] and lower e’ velocity [7.7 (±2.5)
vs. 9.6 (±3.4) cm/sec, P < 0.001]. In multivariate logistic
regression analyses, E:e’ and e’ velocity were associated
with SEC independent of LVEF, LAVI, CHADS2 score,
and warfarin therapy (Table 4), with similar results when
substituting the CHA2DS2-VASc for the CHADS2 score.
Diagnostic performance: ROC analyses
The receiver operator characteristics (ROC) curves dem-
onstrated that the E:e’ and e’ velocity have good discrim-
inatory capacity in predicting LAAT with respective
areas under the curve (AUC) of 0.72 and 0.74, which
trended to be larger than the 0.65 AUC associated with
the CHADS2 score (P = 0.17 and 0.052, respectively), as
shown in Figure 4. In this population, the ROC curve
point-coordinates identified an E:e’ value of ≥9.4 to have
100% sensitivity and 38% specificity for LAAT; whereas
E:e’ ≥ 15 was associated with a specificity of 78% at the
Figure 3 Prevalence of left atrial appendage thrombus based on E:e’ ratio and e’ velocity.
Table 3 Multivariate analysis: Predictors of left atrial appendage thrombus
Odds-Ratio 95% CI P value
Clinical Model 1
CHADS2 Score (per 1 point) 1.47 1.04 – 2.1 0.03
Warfarin 3.1 1.0 – 9.6 0.051
Clinical, E/e’, and 2-D echo Model-2
E/e’ (per 1 point) 1.14 1.05 – 1.2 0.002
CHADS2 score (per 1 point) 1.36 0.9 – 2.0 0.10
Warfarin 3.5 1.05 – 11.8 0.04
Model-3*
E/e’ (per 1 point) 1.14 1.03 – 1.3 0.009
LVEF (per 10 point) 0.62 0.4 – 0.9 0.008
LAVI (per 10 mL/m2) 1.59 1.1 – 2.3 0.02
CHADS2 score (per 1 point) 0.93 0.6 – 1.5 0.74
Warfarin 2.73 0.7 – 10.7 0.15
Clinical, e’ velocity, and 2-D echo Model 4
e’ velocity (per 1 cm/sec) 0.70 0.6 – 0.9 0.004
CHADS2 score (per 1 point) 1.27 0.9 – 1.8 0.20
Warfarin 2.87 0.9 – 9.5 0.08
Model 5*
e’ velocity (per 1 cm/sec) 0.68 0.5 – 0.9 0.007
LVEF (per 10 point) 0.67 0.5 – 1.01 0.03
LAVI (per 10 mL/m2) 1.89 1.3 – 2.8 0.002
CHADS2 score (per 1 point) 0.86 0.5 – 1.4 0.53
Warfarin 2.1 0.6 – 7.9 0.26
CI: confidence intervals; LVEF: left ventricular ejection fraction (%); LAVI: left atrial volume index (mL/m2). *The Hosmer and Lemeshow test of the final models
(3 and 5) showed good fit (P values = 0.91and 0.76, respectively).
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Table 4 Multivariate analysis: Predictors of spontaneous echo contrast
Odds-Ratio 95% CI P value
Clinical Model-6
CHADS2 Score ( per 1 point) 1.39 1.2 – 1.7 0.001
Warfarin 2.22 1.4 – 3.7 0.002
Clinical, E/e’, and 2-D echo Model-7*
E:e’ (per 1 point) 1.07 1.002 - 1.1 0.04
LVEF (per 10 point) 0.95 0.8 – 1.2 0.63
LAVI (per 10 mL/m2) 1.53 1.13 – 2.1 0.006
CHADS2 ( per 1 point) 1.22 0.9 – 1.6 0.20
Warfarin 2.06 1.01 – 4.2 0.048
Clinical, e’ velocity, and 2-D Echo Model-8*
e’ velocity (per 1 cm/sec) 0.85 0.7 – 0.97 0.01
LVEF (per 10 point) 1.0 0.8 – 1.2 0.98
LAVI (per 10 mL/m2) 1.61 1.2 – 2.2 0.002
CHADS2 ( per 1 point) 1.18 0.9 – 1.6 0.29
Warfarin 1.94 0.94 – 4.0 0.07
CI: confidence intervals; LVEF: left ventricular ejection fraction (%); LAVI: left atrial volume index (mL/m2). *The Hosmer and Lemeshow test of the final models
(7 and 8) showed good fit (P values = 0.25 and 0.75, respectively).
Figure 4 Receiver operating characteristic curves. AUC: area
under the curve; CI: confidence intervals. The receiver operating
characteristic curves associated with the E:e’ ratio and CHADS2 score
were not statistically different (P = 0.17); whereas the difference
between the curves associated with e’ velocity and the CHADS2
score was borderline significant (P = 0.07).
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was associated with 100% sensitivity for LAAT (Figure 4).
Only a CHADS2 score of zero was “protective” from LAAT.
Discussion
This retrospective cohort study of patients with nonvalv-
ular AF demonstrates that the Doppler diastolic function
parameters of E:e’ and e’ velocity are associated with
LAAT formation and SEC independent of LVEF, LA vol-
ume, and other clinical predictors such as CHADS2 (or
CHA2DS2-VASc) score and warfarin use. Furthermore,
diastolic function parameters seem to negate the predict-
ive value of the CHADS2 or CHA2DS2-VASc score. If
prospectively validated, these findings would indicate
that echocardiographic diastolic function parameters
may help physicians identify patients at very low risk of
LAAT, given their excellent sensitivity. Previous reports
have demonstrated that reduced LVEF is associated with
LAAT [7,19,20]. Despite the fact that E:e’ and e’ velocity
are tightly related to systolic function, [18] we demon-
strated that diastolic parameters are associated with
LAAT independent of LVEF, likely driven by subjects
with impaired diastolic function but preserved LVEF.
Furthermore, the study findings are consistent with a re-
cently published study by our group demonstrating that
B-type Natriuretic Peptide, a surrogate for LVFP, is pre-
dictive of LAAT [21]. These findings are physiologically
plausible, as atrial emptying is likely to be diminished
with impaired diastolic relaxation and elevated LVFP,
leading to atrial blood stasis and thrombus formation.
This pathophysiology was the basis for the study
hypothesis.After the inception of this study Iwakura et al. re-
ported that E:e’ is associated with LAAT independent of
other echocardiographic parameters such as LVEF and
LA dimensions [22]. Our investigation not only confirms
these findings, but also demonstrates the independent
association between diastolic function parameters and
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predictors.
A previous report has demonstrated that permanent
AF is an independent predictor of LAAT, [23] a finding
that was not confirmed in our study (Table 1). We sus-
pect that permanent AF status is no more than a con-
founder for severe left ventricular systolic and diastolic
impairment and left atrial enlargement.
This study showed an association between warfarin
use and LAAT (Model-1). Clearly, this is not a cause
and effect relationship, but rather it is the result of a
clinical bias as physicians are likely to use warfarin in
patients perceived to be at high risk for LAAT and
stroke. This association dissipated once we introduced
diastolic parameters, LVEF and LAVI into the regression
model.
The authors are cognizant of the small sample size
and infrequent LAAT events, which impaired our ability
to analyze many covariates within a single regression
model. Thus, we meticulously chose the covariates to be
analyzed in the logistic regression models and we ap-
plied rigorous examination of the goodness of fit of all
these models. Nevertheless, it is plausible that some
weakly associated parameters may have been missed.
Furthermore, the secondary SEC endpoint analyses were
consistent with the primary endpoint analyses; thus add-
ing validity to the study conclusions. Moreover, we chose
not to test E:e’ and e’ velocity within a single regression
model, as the inherent co-linearity between these indices
is likely to negate the effects of one another. However,
we demonstrated that the predictive values of regression
models containing E:e’ and e’ velocity (Models 3 and 5)
are similar. Our data does not demonstrate significant
superiority of either parameter.
LAVI was shown to be a strong independent predictor
of LAAT in multiple reports; [7,8] a finding that was
confirmed in this study. However, the predictive value of
LAVI was greater when tested with e’ velocity (Model-5)
vs. E:e’ (Model-3). This slight discrepancy is explained
by the fact that left atrial enlargement is, in part, a mani-
festation of elevated LVFP assessed by E:e’ [18,24]. Thus,
LAVI lost some of its predictive value after adjusting for
E:e’. On the other hand, LAVI was a stronger predictor
(OR = 1.89 per 10 mL/m2) when e’ velocity (rather than
E:e’) was included in Model-5 (Table 3). This seems
plausible since e’ velocity in itself is not a measure of
LVFP. These findings further support the hypothesis that
surrogate measures of LVFP such as LAVI, E:e’ or B-type
natriuretic peptide are important predictors for LAAT.
Predicting LAAT is certainly important in some clin-
ical scenarios, such as prior to electrical cardioversion
[25,26]. Since LAAT is the source of the majority of sys-
temic thromboembolic events in patients with AF, [2,3]
it is plausible that diastolic function parameters (E:e’ ande’ velocity) can also help predict embolic stroke. We
speculate that, in nonvalvular AF, diastolic impairment
and elevated LVFP represent the link between CHADS2
risk factors and systemic embolism [27]. We are fully
aware that the patient population in this study is dis-
tinctly different from that of the AF patient population
at large. Furthermore, although LAAT is a precursor of
systemic thromboembolism and stroke, [28,29] these
endpoints are not necessarily interchangeable. Further
validation of this concept in a prospective hard endpoint
(stroke) outcome study is warranted.
Our study has a few limitations. First, the retrospective
design is an obvious limitation. Second, although the
majority of the TTEs were performed within a few days
prior to the TEE, some preceded the TEE by as long as
12 months. Thus, the loading conditions at the time of
the TTE and TEE may be different for many subjects.
However, analysis of the relatively “volume independent”
e’ velocity yielded similar results to those observed with
E:e’, [30] supporting the study conclusions. Lastly, the
small sample size and limited number of events consti-
tute another limitation. Therefore, the findings of this
hypothesis-generating study are not applicable clinically
at this time, as they demand prospective validation.
Conclusion
Our investigation demonstrates that the diastolic func-
tion indices of E:e’ and e’ velocity are associated with
LAAT in patients with nonvalvular AF, independent of
clinical and echocardiographic covariates. These findings
need to be externally validated, and could potentially be
incorporated into a prediction rule that could be utilized
clinically for risk stratification for LAAT in patients with
nonvalvular AF.
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